SERA PROGNOSTICS, INC. 8K

Sera Prognostics reported second quarter 2026 financial results marked by continued operating losses but strengthened commercial, policy, scientific, and regulatory positioning for its PreTRM test, supported by a sizable cash balance expected to fund operations through 2029.

Sera Prognostics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, showing modest revenue growth to $30,000 and a net loss of $9.1 million, while highlighting commercial and policy momentum for its PreTRM test, including the launch of a fourth partnership program with a national payer, expanded access through an Illinois Medicaid coverage mandate, new PRIME clinical and health economic data and scientific recognition, progress toward European CE marking, leadership and board enhancements, and a strong liquidity position of approximately $80.3 million in cash, cash equivalents and marketable securities that management believes will fund operations through key commercialization milestones into 2029.

Filing Facts

CIK

1534969

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-346846

Alert Tier

6